Equities Analysts Offer Predictions for Masimo Q1 Earnings

Masimo Co. (NASDAQ:MASI) – Equities research analysts at Zacks Research issued their Q1 2025 earnings per share (EPS) estimates for shares of Masimo in a report issued on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay forecasts that the medical equipment provider will earn $1.25 per share for the quarter. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.47 EPS, FY2025 earnings at $5.32 EPS, Q1 2026 earnings at $1.41 EPS, Q2 2026 earnings at $1.45 EPS, Q3 2026 earnings at $1.44 EPS, Q4 2026 earnings at $1.60 EPS and FY2026 earnings at $5.90 EPS.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million during the quarter, compared to analysts’ expectations of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%.

Other equities analysts have also recently issued reports about the company. Raymond James increased their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Wells Fargo & Company increased their target price on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler increased their target price on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $194.80.

Masimo Stock Down 1.9 %

NASDAQ MASI opened at $169.50 on Friday. The stock has a market cap of $9.14 billion, a PE ratio of 116.90 and a beta of 1.04. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The business has a 50 day moving average price of $175.00 and a two-hundred day moving average price of $158.86. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Institutional Investors Weigh In On Masimo

Large investors have recently added to or reduced their stakes in the stock. Westfield Capital Management Co. LP increased its position in Masimo by 23.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after buying an additional 262,370 shares during the period. National Bank of Canada FI increased its position in Masimo by 195.6% in the third quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider’s stock worth $17,666,000 after buying an additional 87,675 shares during the period. Lecap Asset Management Ltd. acquired a new stake in Masimo in the fourth quarter worth $1,607,000. Nisa Investment Advisors LLC increased its position in Masimo by 16,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider’s stock worth $835,000 after buying an additional 5,022 shares during the period. Finally, Trust Point Inc. acquired a new stake in Masimo in the fourth quarter worth $230,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now directly owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.70% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.